Application of Model-Informed Drug Development in Dose Selection and Optimization for siRNA Therapies

In conclusion, the integration of MIDD offers substantial advantages in navigating the complex challenges of dose selection and optimization in siRNA drug development, which in turn accelerates the development process, supports regulatory decision making, and ultimately improves the clinical outcomes of siRNA-based therapies, fostering advancements in precision medicine across a diverse range of diseases.PMID:38426370 | DOI:10.1002/jcph.2418

Source: The Journal of Clinical Pharmacology - March 1, 2024 Category: Drugs & Pharmacology Authors: Ye Yuan Liang Li Justin Earp Lian Ma Venkatesh Atul Bhattaram Vishnu Sharma Alexander Tong Yaning Wang Jiang Liu Hao Zhu Source Type: research